Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
EDITORIAL
Vladyslava Barzylovych, Tetiana Umanets, Anastasiia Barzylovych, Hanna Hilenko, Viktoria Stelmah, Lesya Besh, Svetlana Nedelskaya, Oleksandr Abaturov, Volodymyr Ditiatkovsky, Hanna Kasianenko, Viktoriia Khomenko, Volodymyr Lapshyn, Yurii Antipkin
No abstract text is available yet for this article.
February 21, 2024: Clinical and Experimental Allergy
#22
JOURNAL ARTICLE
Jennifer L P Protudjer, Helen Brough, Christina J Jones, Mary Jane Marchisotto, Linda J Herbert, Caity Roleston, Rebecca C Knibb
No abstract text is available yet for this article.
February 14, 2024: Clinical and Experimental Allergy
#23
JOURNAL ARTICLE
L Zubiaga-Fernandez, A Testera-Montes, C Rondon, N Perez-Sanchez, F Gomez-Perez, J M Vega-Chicote, J Bartra, M Ferrer, I Eguiluz-Gracia, M J Torres
BACKGROUND: Clinical trials showed the efficacy of 300 mg/4 weeks of omalizumab (OMA) during 6 months in patients with severe chronic spontaneous urticaria (CSU). Nevertheless, in real life, many patients require higher doses and/or longer treatment. This study assesses the real-life performance of OMA in severe CSU and identifies factors associated with the response. METHODS: CSU patients eligible for OMA were recruited prospectively. Clinical data and a blood test were collected before OMA initiation...
February 11, 2024: Clinical and Experimental Allergy
#24
REVIEW
Roselie Achten, Judith Thijs, Marlot van der Wal, Chantal van Luijk, Daphne Bakker, Edward Knol, Matthijs van Luin, Mohsin El Amrani, Eveline Delemarre, Ahmed M I Elfiky, Joke de Boer, Femke van Wijk, Marlies de Graaf, Marjolein de Bruin-Weller
Atopic dermatitis (AD) is a chronic inflammatory skin disease for which new targeted therapies are currently available. Due to the increased rates of ocular surface disease (OSD) reported during treatment with these new targeted treatments, more insight into the occurrence and pathomechanism of OSD in moderate-to-severe AD patients is needed. Therefore, this review's first part highlights that most patients with moderate-to-severe AD already have characteristics of OSD before starting targeted treatment. Remarkably, not all AD patients with OSD report ocular symptoms...
February 8, 2024: Clinical and Experimental Allergy
#25
REVIEW
Sophie A Rosser, Melanie Lloyd, Alice Hu, Paxton Loke, Mimi L K Tang
OBJECTIVE: Understanding factors that impact health-related quality of life (HRQL) is essential to inform personalised food allergy management. However, there are inconsistencies about the impact of gender on HRQL in food allergy. This review aimed to collate all investigations of the association between gender and total or subdomain HRQL scores of individuals with food allergy and their caregivers. DESIGN: This is a narrative systematic review. We descriptively synthesised and compared HRQL outcomes by participant and parent genders according to statistical and clinical significance...
February 7, 2024: Clinical and Experimental Allergy
#26
JOURNAL ARTICLE
Cagatay Karaaslan, Oliver Wirz, Ge Tan, Anna Globinska, Tadech Boonpiyathad, Klaus Hedman, Slavica Vaselek, Maria Söderlund Venermo, Tuomas Jartti, Mubeccel Akdis, Cezmi A Akdis
BACKGROUND: Human bocaviruses (HBoVs) have been demonstrated in respiratory and gastrointestinal infections; however, the immune response to them has not been studied in detail. In this study, we investigated the B cell immune responses to HBoV1 and HBoV2, representing two different species of bocaviruses in humans. METHODS: We analyzed the effects of stimulations with HBoV1 and 2 virus-like particles (VLPs) and of co-stimulation with HBoV1-rhinovirus (RV) on cells of the immune system by flow cytometry, transcriptomics, and luminometric immune assays...
February 6, 2024: Clinical and Experimental Allergy
#27
JOURNAL ARTICLE
Latha Kadalayil, Scott Lowther, Wei Chern Gavin Fong, Frédéric Nicolas, Stephen Potter, Maria Larsson, Ramesh Kurukulaaratchy, Syed Hasan Arshad
No abstract text is available yet for this article.
February 5, 2024: Clinical and Experimental Allergy
#28
JOURNAL ARTICLE
Stefanie Busold, Lorenz Aglas, Charlotte Menage, Réjean Desgagnés, Loïc Faye, Anne-Catherine Fitchette, Esther C de Jong, Caroline Martel, Maria Stigler, Virginie Catala-Stordeur, Guy Tropper, Lydia Auger, Bertrand Morel, Serge A Versteeg, Louis-P Vézina, Véronique Gomord, Janice A Layhadi, Mohamed Shamji, Teunis B H Geijtenbeek, Ronald van Ree
No abstract text is available yet for this article.
January 27, 2024: Clinical and Experimental Allergy
#29
JOURNAL ARTICLE
Witness Dzobo, Efrem Eren, Samuel Robson, Janis K Shute
No abstract text is available yet for this article.
January 25, 2024: Clinical and Experimental Allergy
#30
JOURNAL ARTICLE
Simona Barni, Benedetta Pessina, Luca Scarallo, Sara Renzo, Elena Sofia Pieri, Flavio Labriola, Patrizia Alvisi, Vincenzo Villanacci, Mattia Giovannini, Lucrezia Sarti, Leonardo Tomei, Jacopo Barp, Sara Naldini, Monica Paci, Francesca Mori, Paolo Lionetti
No abstract text is available yet for this article.
January 23, 2024: Clinical and Experimental Allergy
#31
JOURNAL ARTICLE
Annette T Hastie, Andrew C Bishop, Mohammad S Khan, Eugene R Bleecker, Mario Castro, Loren C Denlinger, Serpil C Erzurum, John V Fahy, Elliot Israel, Bruce D Levy, David T Mauger, Deborah A Meyers, Wendy C Moore, Victor E Ortega, Stephen P Peters, Sally E Wenzel, Chad H Steele
INTRODUCTION: Previous bronchoalveolar lavage fluid (BALF) proteomic analysis has evaluated limited numbers of subjects for only a few proteins of interest, which may differ between asthma and normal controls. Our objective was to examine a more comprehensive inflammatory biomarker panel in quantitative proteomic analysis for a large asthma cohort to identify molecular phenotypes distinguishing severe from nonsevere asthma. METHODS: Bronchoalveolar lavage fluid from 48 severe and 77 nonsevere adult asthma subjects were assessed for 75 inflammatory proteins, normalized to BALF total protein concentration...
January 22, 2024: Clinical and Experimental Allergy
#32
JOURNAL ARTICLE
Fares Dashti, Ian Gregory
No abstract text is available yet for this article.
February 2024: Clinical and Experimental Allergy
#33
RANDOMIZED CONTROLLED TRIAL
Marie-Lee Simard, Natalija Novak, Jean-Philippe Drolet, Marie-Claude Joly, Hendrik Nolte, Eike Wuestenberg, Rémi Gagnon
BACKGROUND: Local application site reactions are common with sublingual allergy immunotherapy (AIT)-tablets for the treatment of allergic rhinitis/conjunctivitis (AR/C) and occasionally lead to treatment discontinuation. Because of the lower mast cell density in the vestibular mucosa than the sublingual area, vestibular AIT-tablet administration may result in fewer adverse events (AEs). This pilot study evaluated the tolerability of the vestibular administration route of AIT-tablets compared with the sublingual route in adult subjects with AR/C...
February 2024: Clinical and Experimental Allergy
#34
JOURNAL ARTICLE
Yuxiang Li, Ashley Devonshire, Bin Huang, Sandra Andorf
BACKGROUND: The Learning Early About Peanut Allergy (LEAP) trial showed that early dietary introduction of peanut reduced the risk of developing peanut allergy by age 60 months in infants at high risk for peanut allergy. In this secondary analysis of LEAP data, we aimed to determine risk subgroups within these infants and estimate their respective intervention effects of early peanut introduction. METHODS: LEAP raw data were retrieved from ITNTrialShare.org...
January 19, 2024: Clinical and Experimental Allergy
#35
JOURNAL ARTICLE
W W de Weger, C E M Herpertz, G N van der Meulen, H Bangma, W Kastelijn, L van Lente, G H Koppelman, A B Sprikkelman, A W A Kamps
No abstract text is available yet for this article.
January 19, 2024: Clinical and Experimental Allergy
#36
JOURNAL ARTICLE
Ekaterina Potapova, Salvatore Tripodi, Valentina Panetta, Stephanie Dramburg, Roberto Bernardini, Carlo Caffarelli, Antonella Casani, Rosa Cervone, Loredana Chini, Pasquale Comberiati, Giovanna De Castro, Michele Miraglia Del Giudice, Iride Dello Iacono, Andrea Di Rienzo Businco, Marcella Gallucci, Arianna Giannetti, Viviana Moschese, Ifigenia Sfika, Elena Varin, Riccardo Asero, Annamaria Bianchi, Mauro Calvani, Tullio Frediani, Francesco Macrì, Nunzia Maiello, Francesco Paravati, Umberto Pelosi, Diego Peroni, Giuseppe Pingitore, Mariangela Tosca, Anna Maria Zicari, Giampaolo Ricci, Gerald Reese, Linus Grabenhenrich, Katja Icke, Armin Grübl, Christoph Müller, Fred Zepp, Antje Schuster, Ulrich Wahn, Susanne Lau, Thomas Keil, Paolo Maria Matricardi
BACKGROUND: IgE antibodies to cross-reactive carbohydrate determinants (CCD) are usually clinically irrelevant but they can be a cause of false positive outcomes of allergen-specific IgE tests in vitro. Their prevalence and levels have been so far cross-sectionally examined among adult allergic patients and much less is known about their origins and relevance in childhood. METHODS: We examined CCD with a cross-sectional approach in 1263 Italian pollen allergic children (Panallergen in Paediatrics, PAN-PED), as well as with a longitudinal approach in 612 German children (Multicenter Allergy Study, MAS), whose cutaneous and IgE sensitization profile to a broad panel of allergen extracts and molecules was already known...
January 17, 2024: Clinical and Experimental Allergy
#37
JOURNAL ARTICLE
Aida Santaolalla, Heather J Bax, Jitesh Chauhan, Debra H Josephs, Mieke Van Hemelrijck, Sophia N Karagiannis
No abstract text is available yet for this article.
January 16, 2024: Clinical and Experimental Allergy
#38
JOURNAL ARTICLE
Johanna Heldin, Andrei Malinovschi, Shadi Amid Hägg, Thorarinn Gíslason, Bryndís Benediktsdóttir, Robert Movérare, Jenny Hallgren, Magnus Molin, Rain Jogi, Christer Janson
No abstract text is available yet for this article.
January 8, 2024: Clinical and Experimental Allergy
#39
JOURNAL ARTICLE
Maria R Strobl, Hilal Demir, Gordana Wozniak-Knopp, Andrea Wangorsch, Florian Rüker, Barbara Bohle
INTRODUCTION: Allergen-specific IgE-blocking IgG antibodies contribute to successful allergen immunotherapy (AIT), however, not much is known about their affinity. Since affinity measurements of polyclonal antibodies in serum are technically challenging we evaluated the applicability of acidic disruption of antibody-allergen complexes by a modified ELISA protocol with monoclonal antibodies (mAbs) specific for the relevant major allergens Betv1 and Mald1. Then, AIT-induced blocking and non-blocking Mald1-specific antibodies in sera from individuals with or without reduced apple allergy were compared...
January 6, 2024: Clinical and Experimental Allergy
#40
JOURNAL ARTICLE
Joshua Gardner, Sean Hammond, Rebecca Jensen, Andrew Gibson, Matthew S Krantz, Michael Ardern-Jones, Elizabeth J Phillips, Munir Pirmohamed, Amy E Chadwick, Catherine Betts, Dean J Naisbitt
BACKGROUND: Vancomycin, a glycopeptide antibiotic used for Gram-positive bacterial infections, has been linked with drug reaction with eosinophilia and systemic symptoms (DRESS) in HLA-A*32:01-expressing individuals. This is associated with activation of T lymphocytes, for which glycolysis has been isolated as a fuel pathway following antigenic stimulation. However, the metabolic processes that underpin drug-reactive T-cell activation are currently undefined and may shed light on the energetic conditions needed for the elicitation of drug hypersensitivity or tolerogenic pathways...
January 4, 2024: Clinical and Experimental Allergy
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
